Dr. David Shelton joins Distributed Bio's scientific advisory board

San Francisco, CA: November 11th, 2015

Distributed Bio are delighted to announce that Dr David Shelton has joined our team as a scientific advisor. Dr Shelton has been a leader in biotherapeutics discovery for over 30 years, taking multiple programs in pain, hypercholesterolemia and oncology from discovery to late stage clinical trials.

David Shelton, Ph.D. is the former Vice President of Biology in the Rinat Laboratories, Pfizer Worldwide Research and Development. Rinat Laboratories is a Pfizer biotech unit and he was responsible for drug discovery and development through Phase 3.

Dr. Shelton received his Ph.D. in Neuroscience from the University of California, San Francisco in 1985, and continued his studies of nerve growth factor (NGF) as a post-doctoral fellow with Dr. Eric Shooter at Stanford University. In 1989 he joined Genentech as a Scientist, contributing to the NGF clinical trial, the first generation of agonist monoclonal antibodies and was heavily involved in developing the rationale for NGF inhibition as a pain therapy. He was among the first employees of Rinat Neuroscience in 2001 and as a Director and Senior Director, he successfully led efforts on RN624 (Tanezumab) for pain. He joined Pfizer in 2006 upon the Rinat acquisition and in addition to continuing involvement with the Tanezumab clinical program, has led the group that developed monoclonal antibodies against PCSK9 for hypercholesterolemia and CGRP for migraine and several other clinical stage programs. Through these programs, he has been involved in integrating biologics into the primary care portfolio as well as developing new biologics for oncology.